ClinicalTrials.gg

Program

brenipatide

Also written as “Brenipatide” and “LY3537031”.

Its studies are mostly in Depressive Disorder, Major · Irritable Bowel Syndrome · Alcoholism · Obesity · Asthma, led by Eli Lilly.

Furthest: phase 3, since Oct 13, 202519 company-led studies, 16 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly1916 open or runningphase 3since Oct 13, 2025Nov 24, 2020Nov 2026phase 1 · NCT06606106
  • Named in Eli Lilly’s own pipeline as Brenipatide, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Nov 24, 2020.

  1. Aug 27, 2024Phase 1 study in OverweightNCT06606106 · 302 enrolled · United States
  2. Sep 3, 20253 phase 1 studiesNCT07165015, NCT07165002, NCT07202871
  3. Oct 13, 20252 phase 3 studies in AlcoholismNCT07219966, NCT07219953
  4. Oct 20, 20252 phase 2 studiesNCT07219173, NCT07223840
  5. Nov 21, 2025Phase 2 study in Bipolar DisorderNCT07286175 · 400 planned · United States, Argentina, Brazil and more
  6. Feb 6, 2026Phase 3 study in Depressive Disorder, MajorNCT07412756 · 1,000 planned · United States, Australia, Brazil and more
  7. Feb 6, 20262 phase 2 studiesNCT07410507, NCT07420283
  8. Mar 13, 2026Phase 1 study in ObesityNCT07476118 · 150 enrolled · United States
  9. Apr 16, 20262 phase 2 studies in Irritable Bowel SyndromeNCT07545772, NCT07545759
  10. Aug 7, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07759245 · 606 planned · United States, Argentina, Austria and more
  11. Aug 14, 2026Phase 3 study in Depressive Disorder, MajorNCT07775300 · 1,000 planned · United States, Australia, Brazil and more
  12. Sep 30, 2026Primary completion moved from 2026-07 to 2026-11Date moved laterphase 1 · +4 months · NCT06606106
  13. Sep 30, 2026Primary completion moved from 2026-08 to 2026-11Date moved laterphase 1 · +3 months · NCT07165002
  14. Nov 5, 2026Phase 2 study in Depressive Disorder, MajorNCT07928245 · 330 planned · United States, Bulgaria, Hungary and more

Ahead

  1. Nov 2026Primary completion: phase 1 study in Hepatic InsufficiencyNCT07165002
  2. Nov 2026Primary completion: phase 1 study in OverweightNCT06606106
  3. Feb 2027Primary completion: phase 1 study in ObesityNCT07476118
  4. Feb 2027Primary completion: phase 2 study in SmokingNCT07223840

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07928245Depressive Disorder, Major · United States, Bulgaria, Hungary and more2Not yet recruitingMay 2028330
NCT07775300Depressive Disorder, Major · United States, Australia, Brazil and more3RecruitingDec 20281,000
NCT07759245Pulmonary Disease, Chronic Obstructive · United States, Argentina, Austria and more2RecruitingMay 2028606
NCT07545772Irritable Bowel Syndrome · United States, Belgium, Canada and more2RecruitingJul 2027342
NCT07545759Irritable Bowel Syndrome · United States, Belgium, Canada and more2RecruitingSep 2027531
NCT07476118Obesity · United States1Active, not recruitingFeb 2027150
NCT07420283Opioid-Related Disorders · United States, Canada, Puerto Rico and more2RecruitingMar 2028465
NCT07412756Depressive Disorder, Major · United States, Australia, Brazil and more3RecruitingFeb 20281,000
NCT07410507Schizophrenia · United States, Argentina, Brazil and more2RecruitingNov 2027450
NCT07286175Bipolar Disorder · United States, Argentina, Brazil and more2RecruitingNov 2027400
NCT07223840Smoking · United States, China, Japan2RecruitingFeb 2027222
NCT07219173Asthma · United States, Argentina, Brazil and more2RecruitingApr 2028531
NCT07219966Alcoholism · United States, Belgium, China and more3RecruitingApr 20281,100
NCT07219953Alcoholism · United States, Belgium, China and more3RecruitingApr 20281,100
NCT07202871Healthy · Singapore1CompletedJul 17, 202647
NCT07165015Renal Insufficiency · United States, New Zealand1CompletedApr 16, 202631
NCT07165002Hepatic Insufficiency · Hungary, New Zealand, Slovakia1RecruitingNov 202632
NCT06606106Overweight · United States1Active, not recruitingNov 2026302
NCT04648865Healthy · Japan1CompletedJun 4, 202140

How it is read

Names in the registry

  • “Brenipatide”, 11 entries
  • “LY3537031”, 10 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.